Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434

Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the American Neurological Association Annual Meeting in Baltimore. The clinical trial involved people with Multiple System Atrophy (MSA), a rare brain condition that makes movement, balance, and some bodily functions much harder over time. 77 adult participants took part; they were randomly divided into groups to receive either ATH434 at two different doses (50mg or 75mg) or a placebo (dummy pill) for 12 months.

The data showed that ATH434 helped slow the worsening of MSA symptoms. It also made it easier for patients to continue their day-to-day activities. Improvements were seen in patients’ scores on the activities of daily living scale (UMSARS Part I, a tool that measures disability in everyday tasks). People taking ATH434 also showed better movement and maintained function in their outpatient activities, as tracked by wearable sensors.

The drug was easy for patients to tolerate, and the rate of side effects was similar to those seen in the placebo group; no serious problems were linked to taking ATH434. This drug is the first medication, with a “Fast Track” status from the FDA, that can slow the progression of MSA.

Alterity Therapeutics Limited (NASDAQ:ATHE) is a biotechnology company that develops disease-modifying treatments for neurodegenerative disorders. Its lead drug candidate is ATH434, which has FDA Fast Track and Orphan Drug designations.

While we acknowledge the potential of ATHE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Conservative Stock Portfolio: 11 Best Stocks to Buy Now and 10 Best Performing Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.